1. Scrip
  2. >>Business
  3. >>Deals

Gilead Decides On Bigger Dance Floor With Tango

Immuno-Oncology Collaboration Expands To Up To 15 Novel Targets

 
• By Joseph Haas

Gilead is making a $20m equity investment in Tango, with the biotech’s series B backers also increasing their investments.

Feet of professional tango dancers in dancing movement on bright background indoors
A discovery deal between Gilead and Tango is turning into a dance marathon

Promising early results from a target discovery collaboration with Gilead Sciences, Inc. are yielding multiple windfalls for Tango Therapeutics, Inc. – Gilead is increasing the size and scope of the original collaboration inked in 2018, it is making a $20m equity investment in Tango, and that is prompting Tango’s existing series B backers to purchase further equity to maintain their ownership proportion in the biotech.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Novartis Doubles Down On Push For Higher Drug Prices In Europe

 
• By Jessica Merrill

CEO Vas Narasimhan urged European governments to spend more to support drug innovation during Novartis's first-quarter results call.

Zai’s R&D Head Touts ‘Beauty’ Of Novel Internal Assets

 
• By Dexter Jie Yan

Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.

BridgeBio Takes A Victory Lap With First Full Quarter Of Attruby Sales

 
• By Mandy Jackson

BridgeBio reported $36.7m in Q1 2025 sales of its ATTR-CM drug Attruby, tripling consensus forecasts. Vyndaquel-maker Pfizer acknowledged the product’s impact during the quarter.